Get Allogene Therapeutics alerts:A number of equities research analysts recently weighed in on the stock. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Allogene Therapeutics in a report on Monday, August 4th. Allogene Therapeutics has a 52 week low of $0.86 and a 52 week high of $3.78. Equities research analysts expect that Allogene Therapeutics will post -1.28 EPS for the current fiscal year. Read MoreReceive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.